Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of “Hold” from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been given a consensus rating of “Hold” by the six analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $19.00.

A number of research analysts have weighed in on ENTA shares. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. HC Wainwright lowered their target price on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. Finally, JMP Securities lowered their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 7th.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $13.14 on Thursday. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $22.13. The stock has a market capitalization of $278.31 million, a PE ratio of -2.11 and a beta of 0.60. The business’s fifty day moving average is $12.73 and its 200 day moving average is $13.04.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.21). Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative return on equity of 64.85%. The firm had revenue of $17.05 million during the quarter, compared to the consensus estimate of $16.47 million. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post -5.95 EPS for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other news, insider Tara Lynn Kieffer sold 7,266 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $12.33, for a total value of $89,589.78. Following the transaction, the insider now owns 32,341 shares of the company’s stock, valued at $398,764.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 13.64% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC raised its stake in Enanta Pharmaceuticals by 3.5% during the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares during the period. Vanguard Group Inc. raised its stake in Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares during the period. Acadian Asset Management LLC raised its stake in Enanta Pharmaceuticals by 1.3% during the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after purchasing an additional 10,952 shares during the period. Krensavage Asset Management LLC raised its stake in Enanta Pharmaceuticals by 6.9% during the 3rd quarter. Krensavage Asset Management LLC now owns 735,103 shares of the biotechnology company’s stock valued at $8,211,000 after purchasing an additional 47,490 shares during the period. Finally, Federated Hermes Inc. bought a new stake in Enanta Pharmaceuticals during the 4th quarter valued at approximately $1,253,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.